ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

durvalumab (16) vs nivolumab (16)22 active2012–2033
durvalumabnivolumab
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompletedTerminatedSuspendedUnknown status
'12
'14
'16
'18
'20
'22
'24
'26
'28
'30
'32
durvalumab
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckP2
HIMALAYAP3
ADRIATICP3
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneP2
IMMUNO-BILP2
FRAIL-IMMUNEP2
ORCHARDP2
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsP2
TRIPLEXP3
PACIFIC-8P3
Immunological Variables Associated to ICI Toxicity in Cancer PatientsP2
DeLLphi-305P3
AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerP3
TREMENDOUS-2P2
SLIDE-HCCP2
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung CancerP2
nivolumab
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)P3
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)P3
CheckMate 143P3
NIVAHLP2
BIONIKKP2
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)P2
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic SignatureP2
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.P2
CheckMate 848P2
CheckMate 7DXP3
NADINAP3
Immunological Variables Associated to ICI Toxicity in Cancer PatientsP2
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyP2
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaP2
LEDANGP3
KRASCENDO 3P3

Upcoming readouts

9 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.
Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.